The BioHub: The Top Voices in Biotech

In this episode of The BioHub Podcast, Max sits down with Amit Etkin, Founder and CEO of Alto Neuroscience.

Psychiatry is one of the few areas in medicine still dominated by trial and error.

Amit is trying to change that.

A trained psychiatrist and neuroscientist, Amit founded Alto to bring precision medicine into mental health — using biomarkers to better match patients with the treatments that actually work for them.

In this conversation, we get into why CNS drug development has historically struggled, what’s broken in the current system, and how a more data-driven approach could reshape the future of psychiatry.

We also talk about Amit’s journey from academia to founder, the realities of building in a tough market, and why now might finally be the turning point for neuroscience.

A thoughtful, honest conversation tackling one of the hardest problems in medicine. 🧠

We were delighted to be joined by James Kim (Chief Corporate Officer) and Ronald Li (Chief Executive Officer), at Medera Biopharmaceuticals.
Medera is a company at the forefront of pharmaceutical innovation, focused on advancing next-generation therapies and building a globally competitive platform across research, development, and commercialization. As the industry continues to evolve — driven by scientific breakthroughs, regulatory complexity, and shifting market dynamics — Medera is positioning itself to play a meaningful role in shaping what comes next.
James and Ronald sit right at the center of that journey. Between them, they bring deep experience across strategy, operations, and scaling healthcare businesses, with a strong focus on translating innovation into real-world impact.

On this episode we welcome Cellares' co-founder, Fabian Gerlinghaus, to discuss their revolutionary, fully automated, cell therapy manufacturing platform.
Cell therapies work - the science is proven. Fabian & the team's mission is to deliver these life-changing therapies at scale, to change more patient's lives.
On this episode we talk through Fabian's background in robotics, his move to California and the life sciences, and how he and co-founder Omar Kurdi started the Cellares story.
Looking ahead, we dig into the technology and, latest milestones (including recently starting GMP manufacturing), whilst also talking through plans for international expansion, and the impressive Series D funding that journey.

Today, we’re joined by Dipal Doshi, a leader at theforefront of modern biotechnology and rare disease innovation. As CEO of Entrada Therapeutics, Dipal has helped build the company from its earliest days into a clinical-stage pioneer focused on unlocking intracellular therapies.
With a career that spans investment banking at MerrillLynch, global pharma at Eli Lilly and Company, and senior leadership roles at Amicus Therapeutics, Dipal brings a unique blend of financial, strategic, and commercial expertise to the biotech world.
Now Dipal's leading Entrada Therapeutics, who are aclinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, they are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others.

In this episode of The BioHub Podcast, Max sits down with Barry Quart, CEO of Connect Biopharma and one of the most experienced biotech leaders in the industry.

Barry’s career spans more than three decades across biotech and pharma, including founding Ardea Biosciences (acquired by AstraZeneca) and leading Heron Therapeutics, where he helped bring multiple drugs through development and approval. Across his career he has played a role in nine FDA-approved medicines.

In this conversation, Barry shares the lessons he’s learned building biotech companies, what it really takes to develop successful drugs, and how he thinks about leadership in an industry defined by risk and long timelines.

They also dive into Connect Biopharma, the company’s strategy in inflammatory diseases, and the potential of their lead program targeting the IL-4 pathway in asthma and other respiratory conditions.

It’s a conversation about building companies, developing medicines, and navigating the realities of biotech.